Skip to main content

Table 2 Patients’ characteristics and their relation to tamoxifen response

From: Her2/EGFR-PDGFR pathway aberrations associated with tamoxifen response in metastatic breast cancer patients

Feature Responders (78) Refractory (79) P value
Age (years)
 > 50 (81) 40 (51.3%) 41 (51.9%) 1.0
 ≤ 50 (76) 38 (48.7%) 38 (48.1%)
Menstrual status
 Pre (73) 36 (46.2%) 37 (46.8%) 1.0
 Post (84) 42 (53.8%) 42 (53.2%)
Histological grade
 II (114) 57 (73.1%) 57 (72.2%) 0.69
 III (43) 21 (26.9) 22 (27.8%)
Contraception
 Yes (31) 17 (21.8%) 14 (17.7%) 0.55
 No (126) 61 (78.2%) 65 (82.3%)
Her-2 status
 +ve (58) 31 (39.7%) 27 (34.2%) 0.51
 −ve (99) 47 (60.3%) 52 (65.8%)
ER
 +ve (108) 52 (66.7%) 56 (70.9%) 0.61
 −ve (49) 26 (33.3%) 23 (29.1%)
PR
 +ve (78) 38 (48.7%) 40 (50.6%) 1.00
 −ve (79) 40 (51.3%) 39 (49.4%)
Disease site
 Bone only (46) 31 (39.7%) 15 (18.9%) 0.005*
 Visceral (111) 47 (60.3%) 64 (81.1%)